Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year?

Core Insights - Armata Pharmaceuticals, Inc. (ARMP) is showing strong performance compared to the Medical sector, with a year-to-date return of approximately 68.7% against the sector's average of 3.6% [4] - The Zacks Rank for Armata Pharmaceuticals is 2 (Buy), indicating positive analyst sentiment and an improving earnings outlook [3] - The Zacks Consensus Estimate for ARMP's full-year earnings has increased by 24.7% over the past three months, reflecting stronger analyst sentiment [4] Company Performance - Armata Pharmaceuticals is part of the Medical sector, which includes 960 stocks and currently holds a Zacks Sector Rank of 5 [2] - Within the Medical - Biomedical and Genetics industry, which consists of 472 stocks, Armata Pharmaceuticals ranks 79 in the Zacks Industry Rank, outperforming the industry average return of 9.8% year-to-date [6] Comparison with Peers - Halozyme Therapeutics (HALO) is another stock that has outperformed the Medical sector, with a year-to-date increase of 44.3% and a Zacks Rank of 1 (Strong Buy) [5] - Both Armata Pharmaceuticals and Halozyme Therapeutics are positioned well within their industry and are expected to continue their solid performance [7]